Hibiscus Sabdariffa

PreclinicalBiologic

AAin Shams University

Hibiscus Sabdariffa is one of 6 biologic programs targeting Xerostomia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

XerostomiaActive, not recruiting

XerostomiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Xerostomia

#DrugCompanyPhaseTrials

Isopto Carpine

AAdvanz Pharma

Approved

3 2

Decadron

AAspen Global Incorporated

Approved

1 3

Ethyol

LLegacy Health System

Approved

—4

Evoxac

CCosette Pharmaceuticals, Inc.

Approved

1 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 1

1 6

Hibiscus Sabdariffa

AAin Shams University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Xerostomia1 trial

The Efficacy of Hibiscus Sabdariffa in Xerostomia

Recruiting·—·N/A·NCT06413550·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Hibiscus Sabdariffa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hibiscus Sabdariffa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hibiscus Sabdariffa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ain Shams University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: AAin Shams University

Hibiscus Sabdariffa

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Xerostomia1 trial

References

Drug Info

Quick Facts

Related News